361 Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

361 Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14,790	Closed	-$2.21M	–	338
2019 Q4	$2.21M	Buy	14,790 +149	+1%	+$20.3K	0.61%	8
2019 Q3	$1.88M	Sell	14,641 -176	-1%	-$23.6K	0.35%	155
2019 Q2	$2.11M	Sell	14,817 -82	-0.6%	-$11K	0.37%	148
2019 Q1	$2.13M	Buy	+14,899	New	+$1.94M	0.37%	150

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

361 Capital's JAZZ Position: Q1 2020 in Review

361 Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 14,790 shares — an estimated $2.21M sold.

361 Capital first reported a position in JAZZ in Q1 2019 and held it in 4 quarters. The position peaked at $2.21M in Q4 2019. 408 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

361 Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
361 Capital sold 14,790 Jazz Pharmaceuticals shares in Q1 2020, an estimated $2.21M.
361 Capital first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 4 quarters.
361 Capital's Jazz Pharmaceuticals position peaked at $2.21M in Q4 2019.
408 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.